Overview

• Biote Q2 2025 revenue misses analyst expectations, per LSEG data

• Net income rises to $3.9 mln, driven by dietary supplement sales

• Company initiated reorganization to boost clinic and procedure growth

Outlook

• Biote revises 2025 revenue guidance to above $190 mln

• Company expects 2025 adjusted EBITDA above $50 mln

• Biote sees 2025 procedure revenue decreasing at high single-digit rate

• Company forecasts 2025 dietary supplement revenue to grow at mid-teens rate

Result Drivers

• DIETARY SUPPLEMENT SALES - Increased 30.4% year-over-year, contributing positively to revenue

• GROSS MARGIN EXPANSION - Improved to 71.6% due to vertical integration and cost management

• REORGANIZATION - Initiated restructuring to enhance productivity and drive long-term success

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the professional information services peer group is "buy"

• Wall Street's median 12-month price target for Biote Corp is $7.00, about 40.4% above its August 5 closing price of $4.17

• The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nBw4Pl6kya

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)